Achillion Pharmaceuticals (ACHN) : The money flow analysis of Achillion Pharmaceuticals (ACHN) indicates a $0.79 million of outflow was on downticks, whereas, the investors on Tuesday gobbled up stocks worth $1.36 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.73 and so was the total money flow at $0.57 million. The bulls lapped up $0.76 million worth of block trades on upticks. The money flow was $0.76 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Achillion Pharmaceuticals (ACHN), pushing it down by -0.22% for the day. The stock slid $0.02 and traded at $9.19 during the day. Nonetheless, the stock is 0.55% over the previous weeks close.
The company Insiders own 6.52% of Achillion Pharmaceuticals shares according to the proxy statements. Institutional Investors own 81.98% of Achillion Pharmaceuticals shares. In an insider trading activity, The officer (Chief Financial Officer), of Achillion Pharmaceuticals Inc, Fenton Mary Kay had unloaded 43,500 shares at $10.08 per share in a transaction on December 28, 2015. The total value of transaction was $438,480. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Shares of Achillion Pharmaceuticals, Inc. appreciated by 17.41% during the last five trading days but lost 3.25% on a 4-week basis. Achillion Pharmaceuticals, Inc. is up 13.79% in the last 3-month period. Year-to-Date the stock performance stands at -14.37%.
Achillion Pharmaceuticals (NASDAQ:ACHN): stock turned positive on Tuesday. Though the stock opened at $9.3, the bulls momentum made the stock top out at $9.36 level for the day. The stock recorded a low of $9.125 and closed the trading day at $9.24, in the green by 0.33%. The total traded volume for the day was 1,348,202. The stock had closed at $9.21 in the previous days trading.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.